Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: A time and motion study

Hemodialysis International

Volumn 12, Issue 4, 2008, Pages 441-449

  Schiller, Brigitte ^a   Doss, Sheila ^a   De Cock, Erwin ^b   Del Aguila, Michael A ^c   Nissenson, Allen R ^d  

^a University of Minnesota   (United States)

^b United BioSource Corporation   (Spain)

^c HOFFMANN LA ROCHE INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Costs; Drug administration; Erythropoiesis stimulatingagent (ESAs); Personnel time; Resource utilization

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DISEASE ASSOCIATION; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH CARE PRACTICE; HEALTH CARE UTILIZATION; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PATIENT EDUCATION; PATIENT SATISFACTION; PREDICTION; QUESTIONNAIRE; UNITED STATES; WELLBEING;

ANEMIA; COST SAVINGS; DATA COLLECTION; DRUG COSTS; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; RENAL DIALYSIS; TIME AND MOTION STUDIES;

EID: 53549121431     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00308.x     Document Type: Article

References (26)

1. Nurko S. Anemia in chronic kidney disease: Causes, diagnosis, treatment. Cleve Clin J Med. 2006; 73: 289-297.
2. U.S. Renal Data System. USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
3. McCullough PA, Lepor NE. Piecing together the evidence on anemia: The link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med. 2005; 6(Suppl 3): S4-S12.
4. Dean BB, Dylan M, Gano A Jr, Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function: A retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin. 2005; 21: 981-987.
5. Rossert J, Froissart M, Jacquot C. Anemia management and chronic renal failure progression. Kidney Int. 2005; 68(Suppl 99): S76-S81.
6. Bishop M. Sick and tired. Nurs Stand. 2005; 20: 26-27.
7. Besarab A, Aslam M. Should the hematocrit (hemoglobin) be normalized in Pre-ESRD or dialysis patients? Yes! Blood Purif. 2001; 19: 168-174.
8. KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006; 47(Suppl 3): S11-S145.
9. Perlman RL, Finkelstein FO, Liu L, et al. Quality of life in chronic kidney disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005; 45: 658-666.
10. Amgen Inc. Epogen® (epoetin alfa) [package insert]. Thousand Oaks, CA: Amgen Inc.; 2006.
11. Amgen Inc. Aranesp® (darbepoetin alfa) [package insert]. Thousand Oaks, CA: Amgen Inc.; 2005.
12. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987; 316: 73-78.
13. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986; 2: 1175-1178.
14. Powe NR, Griffiths RI, Watson AJ, et al. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol. 1994; 4: 1455-1465.
15. Stevens ME, Summerfield GP, Hall AA, et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease. BMJ. 1992; 304: 474-477.
16. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: Global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant. 2005; 20: 2587-2593.
17. Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin. 2006; 22: 837-842.
18. Meehan KR, Tchekmedyian NS, Smith RE, Kallich J. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa. Clin Drug Investig. 2006; 26: 593-601.
19. De Francisco AL, Sulowicz W, Klinger M, et al. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: A randomised, multicentre, multiple-dose, phase II study. Int J Clin Pract. 2006; 60: 1687-1696.
20. Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007; 2: 637-646.
21. U.S. Department of Labor, Bureau of Labor Statistics. May 2005 National Occupational Employment and Wage Estimates. US: U.S. Department of Labor, Bureau of Labor Statistics. Available from: http://www.bls.gov/ oes/current/oes_nat.htm (accessed date: November 16, 2006).
22. De Cock E, Bellinghen L, Standaert B. Assessing provider time for anaemia management of dialysis patients using time & motion methods: a multi-centre observational study in Europe. Value Health. 2002; 6: 581.
23. Duh MS, Mody SH, McKenzie RS, et al. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. Drugs Aging. 2006; 23: 969-976.
24. Kruep EJ, Basskin LE. Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am J Health Syst Pharm. 2005; 62: 2597-2603.
25. Ross TK. Analyzing health care operations using ABC. J Health Care Finance. 2004; 30: 1-20.
26. Udpa S. Activity cost analysis: A tool to cost medical services and improve quality of care. Manag Care Q. 2001; 9: 34-41.